Korea Arlico Pharm Co (XKRX:260660) Net Income (Continuing Operations) : ₩-5,358 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Korea Arlico Pharm Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Korea Arlico Pharm Co's Net Income (Continuing Operations) for the three months ended in Dec. 2024 was ₩-1,749 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-5,358 Mil.

Korea Arlico Pharm Co Net Income (Continuing Operations) Historical Data

The historical data trend for Korea Arlico Pharm Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Korea Arlico Pharm Co Net Income (Continuing Operations) Chart

Korea Arlico Pharm Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income (Continuing Operations)

Get a 7-Day Free Trial

8,371.92

4,929.66

8,034.26

3,060.92

-5,358.05

Korea Arlico Pharm Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-3,910.97	-1,874.21	-2,814.71	1,079.50	-1,748.63

Korea Arlico Pharm Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-5,358 Mil.

Korea Arlico Pharm Co (XKRX:260660) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Korea Arlico Pharm Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Korea Arlico Pharm Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Korea Arlico Pharm Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Korea Arlico Pharm Co Ltd (XKRX:260660) » Definitions » Net Income (Continuing Operations)

Traded in Other Exchanges

N/A

Address

7-21, Baumoe-ro 27-gil, Seocho-gu, Seoul, KOR

Website

http://www.arlico.co.kr

Korea Arlico Pharm Co Ltd is engaged in the business of manufacturing and selling pharmaceuticals products. The company offers products in the area of the circulatory system, antiplatelet, muscle relaxants, diabetes, antibiotic and chemotherapy, allergy and respiratory disease, ointment, vitamin and health supplements, digestive system, and metabolic disease. It provides products in various forms such as tablets, capsules, gel, and cream.

Korea Arlico Pharm Co Headlines

No Headlines